ROS-Activated Compounds as Anti-Cancer Therapeutics

Latent until Activated High level of Selectivity Lower Side Effects Dr. Edward Merino, Associate Professor of Chemistry at the University of Cincinnati, and his team have created a novel strategy for the treatment of leukemia and renal cancers by using highly selective compounds. The compounds selectively trigger toxic reactions in cancer cells with increased reactive oxygen species. Reactive oxygen has been found to be at greater concentrations within these cancers. Due to strategic activation, these hydroqui-modified DNA-modifying agents afford the benefit of an enhanced therapeutic index, both in-terms of enhanced anti-cancer activity and reduced anti-normal cell activity, compared to other agents with a similar mode of action. Thus, this agents design produces lower off-target reactivity towards primary cells. Additionally, the strategy is complementary with other therapies. Since these agents are stable, they are amenable to high throughput screening and can be rapidly developed. For discussions around learning more or licensing this technology, please contact Jill Uhl today. Jill Uhl (513) 558-5621

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More